Gemcitabine

Catalog No.S1714 Synonyms: LY-188011, NSC 613327

Gemcitabine  Chemical Structure

Molecular Weight(MW): 263.2

Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.

Size Price Stock Quantity  
In DMSO USD 130 In stock
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • RNA incorporating drugs induce SG assembly. HeLa cells were treated with the RNA incorporating agents 5-azacytidine (50 uM) and 6-thioguanine (10 uM), or the DNA incorporating agents trifluorothymidine (10 uM) and gemcitabine (100 nM) for 72 h. Subsequently, the cellular localization of the SG marker protein TIAR (green) and the P-body marker protein DCP1 (red) was analyzed. Nuclei were stained with Hoechst. Scale bars represent 20 um.

    Nucleic Acids Res 2014 42(10), 6436-47. Gemcitabine purchased from Selleck.

    Mice were administered either vehicle, gemcitabine (120 mg/kg [PaCa2]) or 20 mg/kg of BBI608 i.p. After killing, tumors were collected after 7 or 14 d of treatment, for Paca-2 and FaDu cells, respectively. Single-cell suspensions were obtained after animal killing and sterile removal of tumors. Live cells were then counted and used to measure their ability to form spheres when cultured in cancer stem cell media.

    Proc Natl Acad Sci USA, 2015, 112(6): 1839-44. Gemcitabine purchased from Selleck.

  • a: KMBC (blue circles) and HuCCT1 (purple squares) cells were plated in 384-well plates (1,000 cells/well), and incubated with varying concentrations of gemcitabine. Cell viability was assessed after 72 h using Cell Titer GloR 2.0 assay. Data represents the average percent cell viability plotted against concentration of drug in nM from 4 replicates for each condition.

    Mol Cancer, 2017, 16(1):22. Gemcitabine purchased from Selleck.

    Immunofluorescent analysis of gemcitabine-induced γH2A.X and 53-BP1 focus formation. a, b Immunofluorescence staining of γH2A.X(green), 53-BP1 (red), and nuclei staining with DAPI (blue) in T24 (a) and T24r GEMCI20 (b) cells after the indicated treatments. Scale bar = 50 μm

    J Exp Clin Cancer Res, 2017, 36(1):1. Gemcitabine purchased from Selleck.

  • Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Gemcitabine for 48h. Cell survival was measured by a standarad MTT assay.

    Dr. Helen Sadik of Johns Hopkins University. Gemcitabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.
In vitro

Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NGnCRXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHMTWM2OD1yLkCwNFQ2QCCwTR?= MnXlV2FPT0WU
ES4 NYHqSWFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHGzOJRKSzVyPUCuNFAxPjV|IH7N NUfyZXEyW0GQR1XS
ACHN Ml3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTBwMECwPFg4KG6P NWrmU5RkW0GQR1XS
KYSE-510 NFjGUYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHz6V3FKSzVyPUCuNFAxQTd3IH7N M2iwOnNCVkeHUh?=
EW-7 MoPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwMECyOVghdk1? NIe0eJBUSU6JRWK=
BFTC-905 NGnadYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwMEC1NVUhdk1? NHy4fVRUSU6JRWK=
KE-37 M{LV[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHGT2twUUN3ME2wMlAxPTZzIH7N MmLTV2FPT0WU
SBC-5 NHXTdpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTKZZJJUUN3ME2wMlAxPTdibl2= MUnTRW5ITVJ?
NKM-1 NVfMdoJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LXcGlEPTB;MD6wNFcxQSCwTR?= M4rnW3NCVkeHUh?=
RH-1 NH3OZYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\JVY1GUUN3ME2wMlAxPzF6IH7N Mne3V2FPT0WU
ALL-PO M{jZRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrwXZBKSzVyPUCuNFA5OyCwTR?= M1Tmd3NCVkeHUh?=
QIMR-WIL M4i2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nOemlEPTB;MD6wNFg6PCCwTR?= M3nOT3NCVkeHUh?=
A375 NGjRdJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TRWmlEPTB;MD6wNFk6PSCwTR?= MmDyV2FPT0WU
SIG-M5 MoDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTBwMEGwOEBvVQ>? MofBV2FPT0WU
KGN M3n6PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfqbZlKSzVyPUCuNFExQCCwTR?= MlO4V2FPT0WU
EW-13 MofkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2OzNmlEPTB;MD6wNVEzKG6P NIfCVVdUSU6JRWK=
NCI-SNU-1 M3e1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Trb2lEPTB;MD6wNVYhdk1? M3XhdHNCVkeHUh?=
PSN1 NWjLVnZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDGTWM2OD1yLkCxOlUhdk1? MUDTRW5ITVJ?
HUTU-80 M3zMNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwMEG2OkBvVQ>? NV7VR|JOW0GQR1XS
EW-16 NIi2NpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\wS2lEPTB;MD6wNlMhdk1? M2\BfXNCVkeHUh?=
786-0 NUPU[mdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzJTWM2OD1yLkCyN{BvVQ>? MVnTRW5ITVJ?
ES1 M2rIWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fNZWlEPTB;MD6wNlY5KG6P M{iwU3NCVkeHUh?=
RKO NEPtZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\JSnpKSzVyPUCuNFI4QSCwTR?= NYHTNHVCW0GQR1XS
ESS-1 MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3i3[GlEPTB;MD6wNlg3KG6P MUfTRW5ITVJ?
SK-UT-1 NHThT3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37ZUWlEPTB;MD6wNlk4KG6P Mln4V2FPT0WU
LB2241-RCC MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TKTmlEPTB;MD6wN|E5KG6P MYTTRW5ITVJ?
CHL-1 MkDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\XOWlEPTB;MD6wN|I1KG6P NFyzUmlUSU6JRWK=
SW1783 NHizOW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLRTWM2OD1yLkCzN|Yhdk1? MYrTRW5ITVJ?
MEL-JUSO NXzJSmpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwMEO5NUBvVQ>? NHXRbIFUSU6JRWK=
HT-29 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF32SYJKSzVyPUCuNFQyOyCwTR?= NGnPb3lUSU6JRWK=
SNG-M M2qxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwMESyOUBvVQ>? NX2wPY1yW0GQR1XS
TE-15 M1jTfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwMES2OEBvVQ>? NE\rO4xUSU6JRWK=
HOS MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TBRWlEPTB;MD6wOFghdk1? M2HtZ3NCVkeHUh?=
BB65-RCC NH65XYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLqepdKSzVyPUCuNFUyOiCwTR?= NWHSWnF5W0GQR1XS
HCE-4 NGHyVHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLZTWM2OD1yLkC1Nlghdk1? M2eybHNCVkeHUh?=
MHH-ES-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTvTWM2OD1yLkC1N|Ehdk1? M3e5WHNCVkeHUh?=
RPMI-7951 NIi5[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwMEW0NUBvVQ>? M1G0PHNCVkeHUh?=
IST-SL2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwMEW4OEBvVQ>? M3L1dXNCVkeHUh?=
CMK MnXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3jcGlKSzVyPUCuNFU5PiCwTR?= MnHoV2FPT0WU
GR-ST NETB[2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;0b2lEPTB;MD6wOVk2KG6P MkHrV2FPT0WU
NALM-6 M1ntbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2npZWlEPTB;MD6wOlIzKG6P MY\TRW5ITVJ?
RPMI-6666 NYr0Z2NTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPCTWM2OD1yLkC2OVIhdk1? NFv5THVUSU6JRWK=
LC-2-ad MoH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHQTWM2OD1yLkC2OVMhdk1? NVr5UWsxW0GQR1XS
ARH-77 NXzvRVBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDHTWM2OD1yLkC3NVEhdk1? M4LzXnNCVkeHUh?=
IST-MEL1 NUnXfZBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;YNGlEPTB;MD6wO|I3KG6P MUHTRW5ITVJ?
SW1710 Ml\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPwTWM2OD1yLkC3OVEhdk1? MonhV2FPT0WU
DEL Mnr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHji[3lKSzVyPUCuNFg5PyCwTR?= M370dXNCVkeHUh?=
AGS NUnHfGRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHWO|lKSzVyPUCuNFkxOiCwTR?= MY\TRW5ITVJ?
NCI-H2122 NYKxcJp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnwb|hKSzVyPUCuNFk1PiCwTR?= M1nwPXNCVkeHUh?=
HSC-4 NEHl[oJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTBwMUCyJI5O NHr6UINUSU6JRWK=
AM-38 MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIH4bIZKSzVyPUCuNVIyKG6P MYPTRW5ITVJ?
769-P NG\nRYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwMUKzJI5O M1HuenNCVkeHUh?=
RT-112 M3fJWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTiTWM2OD1yLkGyO{BvVQ>? NWrEUHV2W0GQR1XS
MCF7 MnLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkH1TWM2OD1yLkGzOkBvVQ>? MYnTRW5ITVJ?
IGROV-1 M33YZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTBwMUS1JI5O M3\lOHNCVkeHUh?=
OCI-AML2 M4DCXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwMUS3JI5O MVjTRW5ITVJ?
NCI-H1299 NX\wOHFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwMUW3JI5O NGjoO|BUSU6JRWK=
A431 NHnHfHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHKzfJFKSzVyPUCuNVg{KG6P NVqydZZIW0GQR1XS
SW982 NFXj[pBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwMkGzJI5O NIGyd2dUSU6JRWK=
BB30-HNC NWnJNY5WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\FfGJKSzVyPUCuNlMyKG6P MVjTRW5ITVJ?
ACN MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwMkS0JI5O NVnqbGNQW0GQR1XS
647-V MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInLVFRKSzVyPUCuNlQ5KG6P NF;OXm9USU6JRWK=
SK-PN-DW M1zvSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3XTWM2OD1yLkK2OkBvVQ>? MVPTRW5ITVJ?
LCLC-97TM1 MlLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XzemlEPTB;MD6yOlchdk1? M{[5WnNCVkeHUh?=
LB1047-RCC NFjDeXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoL3TWM2OD1yLkK2PUBvVQ>? MYfTRW5ITVJ?
A2780 NVTP[IR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXFZ4FKSzVyPUCuNlchdk1? M4L3bHNCVkeHUh?=
C-33-A M3nLTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXhTWM2OD1yLkK3N{BvVQ>? NYG1dVc6W0GQR1XS
NCI-H2228 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwM{G0JI5O NYLCVpZmW0GQR1XS
TE-5 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHiR|FnUUN3ME2wMlMyPiCwTR?= NYLoN2FzW0GQR1XS
HC-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXqTWM2OD1yLkOyO{BvVQ>? MWjTRW5ITVJ?
SK-MES-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDmWHVKSzVyPUCuN|I5KG6P MXvTRW5ITVJ?
NCI-H1355 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTJN3NKSzVyPUCuN|gyKG6P NGjONGpUSU6JRWK=
YKG-1 NXyyW2RvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4f4XGlEPTB;MD60NVkhdk1? MYPTRW5ITVJ?
RS4-11 MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjOTWM2OD1yLkSzN{BvVQ>? NHLWd2tUSU6JRWK=
Daoy NGrXNYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrqSFhEUUN3ME2wMlQ2PiCwTR?= MkL5V2FPT0WU
A3-KAW MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzPfpc1UUN3ME2wMlU2OSCwTR?= NXS2R2RpW0GQR1XS
SK-MEL-30 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3KzXGlEPTB;MD61OVQhdk1? NGG5OmFUSU6JRWK=
U031 Mor6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIf3WWFKSzVyPUCuOVY2KG6P M1jn[HNCVkeHUh?=
SK-LMS-1 M2f5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPuNlZKSzVyPUCuOVc5KG6P M3yzWnNCVkeHUh?=
ES6 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwNUi2JI5O MYnTRW5ITVJ?
EoL-1-cell M{n2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfZOpdKSzVyPUCuOlE3KG6P MXvTRW5ITVJ?
NCI-H2009 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXO4b5hmUUN3ME2wMlYyQSCwTR?= NUHDPJVOW0GQR1XS
A4-Fuk NYq3PIt7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwNkK2JI5O M2\RU3NCVkeHUh?=
KYSE-270 Mmn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPMTWM2OD1yLk[zOEBvVQ>? NHLMRotUSU6JRWK=
SK-LU-1 NUHySVRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPlWHhKSzVyPUCuOlU2KG6P M37tfHNCVkeHUh?=
SW872 M3vjW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\LZYZ6UUN3ME2wMlc3PSCwTR?= NXLufHZ6W0GQR1XS
ES8 M37ENmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPtPHZvUUN3ME2wMlc5KG6P MUHTRW5ITVJ?
G-402 Ml:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfmclZmUUN3ME2wMlc5PCCwTR?= MY\TRW5ITVJ?
ATN-1 Mn\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PlPWlEPTB;MD64NFchdk1? MoG4V2FPT0WU
DoTc2-4510 MkfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoeyTWM2OD1yLkmwNUBvVQ>? M3;xTnNCVkeHUh?=
MES-SA M1H4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LEPWlEPTB;MD65NFUhdk1? NWXGe|J4W0GQR1XS
SF268 NH6yTJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnjTWM2OD1yLkmyO{BvVQ>? NFv0TVZUSU6JRWK=
SF539 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYWyVopPUUN3ME2xMlAzKG6P Ml3wV2FPT0WU
NB69 Mm\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17vS2lEPTB;MT6wOUBvVQ>? M3HUVXNCVkeHUh?=
8505C M17Hc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTFwME[gcm0> M2izRnNCVkeHUh?=
CAL-12T MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\6UFZJUUN3ME2xMlA5KG6P M1;GXnNCVkeHUh?=
BHY MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnEPVlFUUN3ME2xMlE1KG6P MYrTRW5ITVJ?
LB647-SCLC M1H3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLSXlVKSzVyPUGuNVghdk1? MUDTRW5ITVJ?
CAL-62 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTFwMkKgcm0> MV;TRW5ITVJ?
MEG-01 NY\hOmdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDOTWM2OD1zLkK3JI5O MX3TRW5ITVJ?
MG-63 M4TiSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HDXmlEPTB;MT6zN{BvVQ>? NInFOXdUSU6JRWK=
SW620 NGXQ[Y1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrjfpBiUUN3ME2xMlM2KG6P M2HMSHNCVkeHUh?=
A388 Mn;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTFwM{[gcm0> MXTTRW5ITVJ?
BCPAP Mn\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPldYtKSzVyPUGuOFUhdk1? NESzeplUSU6JRWK=
P30-OHK MkXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDZd2hKSzVyPUGuOFYhdk1? MW\TRW5ITVJ?
Ca9-22 M3jabWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTFwNUSgcm0> NVjMU255W0GQR1XS
VMRC-RCZ NIHJcnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTFwNUSgcm0> NWOzVIpWW0GQR1XS
LOXIMVI M3q0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWP0e295UUN3ME2xMlYhdk1? MlX3V2FPT0WU
L-540 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTFwNjDuUS=> NV\JPGZUW0GQR1XS
NTERA-S-cl-D1 Mo\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\wTWM2OD1zLk[0JI5O NEm2S3JUSU6JRWK=
MFH-ino NFu2OmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPvUlltUUN3ME2xMlY3KG6P M{TlPHNCVkeHUh?=
Calu-6 NFzpSoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFf0RopKSzVyPUGuO|Mhdk1? MoHEV2FPT0WU
HEL M1Lq[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XkdWlEPTB;MT63PUBvVQ>? NH;HVGlUSU6JRWK=
CAL-33 MlrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfwWlJKSzVyPUGuPFkhdk1? NEL3WYtUSU6JRWK=
HSC-3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;BZ3FKSzVyPUGuPVEhdk1? NX3sPI1XW0GQR1XS
KU812 NWL2V5RnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnu4TWM2OD1zLkmxJI5O M1fYNnNCVkeHUh?=
EB2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmL0TWM2OD1{LkCxJI5O MVLTRW5ITVJ?
SR NFX1UnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\QTWM2OD1{LkGyJI5O M4\ERnNCVkeHUh?=
NCI-H2087 NW\FTodXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XCNWlEPTB;Mj6xOEBvVQ>? MoHXV2FPT0WU
H4 NVvBT|l1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTJwMUigcm0> M2P1OXNCVkeHUh?=
EW-1 NGrsT5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPUSolTUUN3ME2yMlIzKG6P MXLTRW5ITVJ?
MC-IXC MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTJwMk[gcm0> MYLTRW5ITVJ?
NCI-H727 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{WxXmlEPTB;Mj61NUBvVQ>? M4noVXNCVkeHUh?=
MRK-nu-1 NH;Ic|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTJwNUegcm0> NUe0SIxwW0GQR1XS
COLO-668 NUG5b|d3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV:3OGhWUUN3ME2yMlY3KG6P NGr3WY5USU6JRWK=
CGTH-W-1 NYLTZ3Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\ad2lEPTB;Mj63NkBvVQ>? M33UNHNCVkeHUh?=
CHP-212 M1[1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLQclN2UUN3ME2yMlc2KG6P NImyRYJUSU6JRWK=
GI-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HUc2lEPTB;Mj63OkBvVQ>? NVrXO|NKW0GQR1XS
HCC1806 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPYTWM2OD1{LkmxJI5O MXXTRW5ITVJ?
HLE NEexVoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLyTWM2OD1|IH7N Mo\jV2FPT0WU
HSC-2 NVvkc2lLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfNTWM2OD1|LkCzJI5O NYnadYVsW0GQR1XS
DMS-273 NEX6bXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTFUolbUUN3ME2zMlA4KG6P MVjTRW5ITVJ?
DU-4475 NF;hc3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2mxXWlEPTB;Mz6xOEBvVQ>? NEnK[Y1USU6JRWK=
LXF-289 M2jtVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rWWWlEPTB;Mz6zNUBvVQ>? NWHXT3Z4W0GQR1XS
PANC-03-27 NEfHfnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3lTWM2OD1|LkWxJI5O Mn3UV2FPT0WU
GAMG MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPaTWM2OD1|Lke0JI5O M4LtNXNCVkeHUh?=
NCI-H522 MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1ztbmlEPTB;ND6zOEBvVQ>? Mle1V2FPT0WU
SW626 NYCxNnZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVThbWYxUUN3ME20MlQ3KG6P NV\XTllGW0GQR1XS
HT-144 MoHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTUTWM2OD12LkmyJI5O NFy1cGZUSU6JRWK=
MEL-HO MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIW1ZY5KSzVyPUWuNVYhdk1? NYfxVoU4W0GQR1XS
BE-13 NWnJWXpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTVwMkGgcm0> NEfWZWhUSU6JRWK=
VA-ES-BJ MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTVwMk[gcm0> M{i4ZXNCVkeHUh?=
NCI-H441 NHLtTHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTjUIFKSzVyPUWuOkBvVQ>? M3;WVXNCVkeHUh?=
KP-4 MlPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXyXGlKSzVyPUWuOlEhdk1? NEPCbYdUSU6JRWK=
LoVo MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\u[|JKSzVyPUWuO|Ehdk1? NX3Pe3RVW0GQR1XS
HT-1080 NXn0emZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3j4eGlEPTB;NT64N{BvVQ>? NGPNU3pUSU6JRWK=
GB-1 M3HJcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\1VmlEPTB;NT64OEBvVQ>? MlzuV2FPT0WU
IA-LM MnKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\zTWM2OD13LkmxJI5O M13QOnNCVkeHUh?=
8-MG-BA NInOTFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\GbWlEPTB;NT65N{BvVQ>? MY\TRW5ITVJ?
SK-HEP-1 M2Px[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDTTWM2OD14LkG0JI5O MWfTRW5ITVJ?
697 NWfBdYVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;tWGJmUUN3ME22MlI2KG6P M{DwcnNCVkeHUh?=
KYSE-450 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVm0bFVUUUN3ME22MlMzKG6P NHzPUoRUSU6JRWK=
HCC2998 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rMUGlEPTB;Nj6zOEBvVQ>? NXX3N40yW0GQR1XS
HD-MY-Z NWrD[ZJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLBTZBTUUN3ME22MlY5KG6P NGTyc2xUSU6JRWK=
OS-RC-2 MnmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTZwNkigcm0> NWnrZ41JW0GQR1XS
SF126 NVjUemUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrxb2pZUUN3ME23MlA2KG6P NF;VSXFUSU6JRWK=
Ca-Ski NILTRoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\ESmlEPTB;Nz6wPUBvVQ>? NWjhNlVXW0GQR1XS
NCI-H358 MmPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjGPG5KSzVyPUeuNVYhdk1? MljnV2FPT0WU
J82 M33GXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXLTWM2OD15LkSxJI5O NVPhcmNbW0GQR1XS
NCI-H2342 Mn7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1e2VmlEPTB;Nz62N{BvVQ>? M37WUHNCVkeHUh?=
OVCAR-8 NFv1UotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\ndIo{UUN3ME23Mlkhdk1? MYHTRW5ITVJ?
TE-8 NGP6dFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13x[2lEPTB;ODDuUS=> M1T3UXNCVkeHUh?=
ETK-1 NUHiR|NTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3YbXB6UUN3ME24MlA5KG6P MW\TRW5ITVJ?
HAL-01 M2TXUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XXdGlEPTB;OD6yJI5O MUjTRW5ITVJ?
KYSE-150 NFrhT5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HJUWlEPTB;OD60O{BvVQ>? M2rGNHNCVkeHUh?=
NCI-H810 M3XqZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjjUYJnUUN3ME24MlU3KG6P M4LtNnNCVkeHUh?=
ONS-76 M{XrO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Pmb2lEPTB;OD62PEBvVQ>? MVnTRW5ITVJ?
NMC-G1 NXL6dIhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXOXJFKSzVyPUiuO|Yhdk1? NEHlc5pUSU6JRWK=
C3A NVz1OI4{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFe1NGNKSzVyPUiuPFQhdk1? MVTTRW5ITVJ?
PA-1 M3\vbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRThwOUmgcm0> MmfYV2FPT0WU
SH-4 NHTyU|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPwXXUzUUN3ME25MlAzKG6P Mk\OV2FPT0WU
EFO-27 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2ewPWlEPTB;OT6wOUBvVQ>? M2H5ZnNCVkeHUh?=
CAPAN-1 M4ewSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zNfWlEPTB;OT6yN{BvVQ>? MX3TRW5ITVJ?
DU-145 M3OzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrvWlB5UUN3ME25MlI6KG6P MUPTRW5ITVJ?
A101D NYXFRYNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TUOGlEPTB;OT6zO{BvVQ>? NEXpXWZUSU6JRWK=
ST486 NUfyUW1mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jLNmlEPTB;OT60NUBvVQ>? MlXnV2FPT0WU
NCI-H1437 NXHs[np{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHGwWGhKSzVyPUmuOFIhdk1? MV;TRW5ITVJ?
HGC-27 M{HDT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37O[GlEPTB;OT62JI5O M2jlNHNCVkeHUh?=
8305C M1y1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HnOmlEPTB;OT62OEBvVQ>? NH3Ib25USU6JRWK=
OCUB-M M1rld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTFyLkCzJI5O MU\TRW5ITVJ?
COLO-679 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrtTWM2OD1zMD6wO{BvVQ>? M{jqV3NCVkeHUh?=
Detroit562 M1rme2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPmTWM2OD1zMD60NkBvVQ>? NVnTPWZ1W0GQR1XS
A204 MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHB[5hKSzVyPUGxMlE3KG6P MX;TRW5ITVJ?
NCI-H1734 NEnZN5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjRV4RKSzVyPUGxMlI6KG6P MorvV2FPT0WU
MC-CAR MlLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTFzLkW4JI5O M{TzbXNCVkeHUh?=
NCI-H2170 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjRTWM2OD1zMT65O{BvVQ>? NVL0VIFSW0GQR1XS
NCI-SNU-5 NWLXbnFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vsVmlEPTB;MUKuNVMhdk1? NX7CNllkW0GQR1XS
HCE-T NH3EXohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXKTWM2OD1zMj60NkBvVQ>? M1[1[XNCVkeHUh?=
KYSE-180 M2rsUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjETWM2OD1zMj64NUBvVQ>? NXLkdWRvW0GQR1XS
C8166 MlPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;vXmlEPTB;MUOuNFghdk1? M4D1T3NCVkeHUh?=
NCI-H460 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjCdGJKSzVyPUGzMlU1KG6P NHOwOIZUSU6JRWK=
SNU-449 NV7kVpNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTF|Lke3JI5O M17Yd3NCVkeHUh?=
MDA-MB-468 NU\4TWJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTF2LkGyJI5O NY[5RlJOW0GQR1XS
COR-L23 NUjBeot3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LJ[2lEPTB;MUSuNVMhdk1? M33xZXNCVkeHUh?=
CTV-1 NFzB[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnnSJF7UUN3ME2xOE4yPCCwTR?= MmfpV2FPT0WU
BL-41 NGrWR5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTF2LkO3JI5O M{TscHNCVkeHUh?=
IGR-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmW3TWM2OD1zND60NkBvVQ>? NH7pS2ZUSU6JRWK=
TK10 M1nuUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTF2LkS5JI5O NYjVV4pWW0GQR1XS
REH MlHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrYflE6UUN3ME2xOE42OSCwTR?= M2nVWnNCVkeHUh?=
LU-139 NUXC[I9ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlX4TWM2OD1zND61PUBvVQ>? NUPqTppwW0GQR1XS
KP-N-YS M2X6Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTF2Lkm3JI5O M1;lcXNCVkeHUh?=
PANC-10-05 NGHDUWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfZd2lxUUN3ME2xOU4{QCCwTR?= NFSx[2xUSU6JRWK=
HL-60 NU[ze454T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvZe2lKSzVyPUG1MlY6KG6P NGHIZXFUSU6JRWK=
T84 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;ycGlEPTB;MUWuPVYhdk1? NHe2VoFUSU6JRWK=
RPMI-8226 NX\mWFQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXmSGhlUUN3ME2xOk4xOiCwTR?= M2m5OnNCVkeHUh?=
UM-UC-3 MkewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVOwfYhXUUN3ME2xOk4yPiCwTR?= MYDTRW5ITVJ?
TE-10 MkG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3Ebnd5UUN3ME2xOk4zOSCwTR?= NX;WZ|VVW0GQR1XS
CAL-148 M2eySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEexUJlKSzVyPUG3MlI{KG6P MkHuV2FPT0WU
BV-173 M{DkV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\1cXVKSzVyPUG3MlI4KG6P M2TzNHNCVkeHUh?=
Calu-3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTF5LkK5JI5O M{HNc3NCVkeHUh?=
RPMI-2650 NVn4dIZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXKOoNjUUN3ME2xO{42QSCwTR?= NVrhUotVW0GQR1XS
MKN45 NV;QdZc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGn4NWFKSzVyPUG3Mlc{KG6P NVH2OXJEW0GQR1XS
NUGC-3 NWXxPY1ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV65XIVMUUN3ME2xPE4{PCCwTR?= NVvGSXd6W0GQR1XS
NCI-H520 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITjbXZKSzVyPUG4Mlc4KG6P M3WzUXNCVkeHUh?=
CCRF-CEM M2n3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTF6Lki1JI5O NUnDeXNkW0GQR1XS
NCI-H2405 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HwS2lEPTB;MUmuNUBvVQ>? NIC4[GZUSU6JRWK=
ES7 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFryTlBKSzVyPUG5Mlc3KG6P MVjTRW5ITVJ?
BPH-1 NFnYUVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfGXYc1UUN3ME2yNE4zQCCwTR?= MVLTRW5ITVJ?
SAS M2LiXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTJyLkWgcm0> NHWwTlNUSU6JRWK=
HuCCT1 NUKxcHI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTJyLkW4JI5O NXPPSJY{W0GQR1XS
LOUCY NGXKb3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJyLk[2JI5O NHztVItUSU6JRWK=
NCI-H292 NF7NWldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnq4TWM2OD1{MD63PUBvVQ>? NWLaOWVIW0GQR1XS
G-361 M3zNcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fybGlEPTB;MkGuNFchdk1? M1rhe3NCVkeHUh?=
M059J MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnQTWM2OD1{MT6wPEBvVQ>? MX\TRW5ITVJ?
NCI-H1651 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTJzLkGxJI5O M{LqN3NCVkeHUh?=
KALS-1 NWXWfHFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTJzLkO5JI5O NGTVc29USU6JRWK=
DJM-1 NYPneYd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPuVlZKSzVyPUKxMlU6KG6P NFmwOlJUSU6JRWK=
AU565 NEHsbZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTqTWM2OD1{MT64N{BvVQ>? MkTIV2FPT0WU
HCC38 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLNTWM2OD1{MT65OUBvVQ>? MWPTRW5ITVJ?
U251 MlPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTJ{LkK3JI5O NYfPWnNsW0GQR1XS
ABC-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTJ{Lk[1JI5O NXTDN3hyW0GQR1XS
SK-NEP-1 NU\xTnRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTIdIlKSzVyPUKyMlk{KG6P NUXm[ZlsW0GQR1XS
CESS NVrlR2x7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHMO4NKSzVyPUKzMlE6KG6P NFH5T3BUSU6JRWK=
MIA-PaCa-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\MPWlEPTB;MkOuN|Yhdk1? MYPTRW5ITVJ?
SUP-T1 Ml7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTJ|LkS3JI5O M3TNSnNCVkeHUh?=
L-428 NI\zOIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmT1TWM2OD1{Mz62NkBvVQ>? M3jsdnNCVkeHUh?=
SW954 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPYTYdNUUN3ME2yN{43QCCwTR?= MlzjV2FPT0WU
HO-1-N-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrwNoJzUUN3ME2yN{44PyCwTR?= Mk\sV2FPT0WU
CHP-126 NULX[W9FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTJ2LkG0JI5O MUDTRW5ITVJ?
HMV-II MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvmTWM2OD1{ND6zOEBvVQ>? NEHtWJJUSU6JRWK=
NB10 NW\qVo9LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HYRmlEPTB;MkSuN|chdk1? NWm0TXFqW0GQR1XS
A172 M3;mUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTJ2LkexJI5O MYPTRW5ITVJ?
MONO-MAC-6 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml21TWM2OD1{ND64OEBvVQ>? M{jLSnNCVkeHUh?=
NCI-H1650 M4fZWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEK2TZZKSzVyPUK1MlQhdk1? NHLBbnFUSU6JRWK=
NH-12 M1;2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TLXGlEPTB;MkWuOUBvVQ>? NFTvV|VUSU6JRWK=
ML-2 M{fuRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLCTWM2OD1{NT63OEBvVQ>? M3\5ZnNCVkeHUh?=
MZ2-MEL NH3zeW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTXTWM2OD1{Nj6yNkBvVQ>? NHnyRXlUSU6JRWK=
COLO-684 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{KyUmlEPTB;Mk[uOFEhdk1? NIHreFlUSU6JRWK=
HuP-T4 NFq3Z5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4m2PGlEPTB;MkeuN{BvVQ>? MV7TRW5ITVJ?
SW837 NXn1Z3VQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXzTWM2OD1{Nz62NkBvVQ>? NG\GWY9USU6JRWK=
MDA-MB-231 NWDzZ5dnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjDU4s5UUN3ME2yO{44QCCwTR?= MWjTRW5ITVJ?
KYSE-140 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHoTWM2OD1{Nz65NUBvVQ>? MUDTRW5ITVJ?
NOMO-1 MkjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\j[JRHUUN3ME2yPE43QCCwTR?= NVe3UpQ2W0GQR1XS
GP5d NUD5eFFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTJ6LkeyJI5O MXLTRW5ITVJ?
COR-L105 NWPDeFEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoP4TWM2OD1{OT60NkBvVQ>? NXjZcVE1W0GQR1XS
LS-411N M4r5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rh[2lEPTB;MkmuPFghdk1? MXjTRW5ITVJ?
NY MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnj1TWM2OD1|MD6xPEBvVQ>? MknpV2FPT0WU
NCI-H2030 MoryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHn2VYVKSzVyPUOwMlQ2KG6P MVrTRW5ITVJ?
CCF-STTG1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{P5OmlEPTB;M{GuOFIhdk1? NHTENJNUSU6JRWK=
NCI-H1703 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHJRpRvUUN3ME2zNU44QCCwTR?= NGfQcoxUSU6JRWK=
TUR NXXp[nNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\OTWM2OD1|Mj6wN{BvVQ>? NVHlTFBlW0GQR1XS
NOS-1 M{m1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGn0cnNKSzVyPUOyMlQ1KG6P NYHBVJliW0GQR1XS
A2058 M324XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTN{LkizJI5O MmG5V2FPT0WU
LCLC-103H NWHXe|lQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTN|LkK1JI5O NGm1blhUSU6JRWK=
NCI-H510A NWfneZpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzr[FRuUUN3ME2zN{4zPyCwTR?= MlnXV2FPT0WU
BC-1 MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTN|Lke3JI5O Mly1V2FPT0WU
SK-CO-1 NGLuZ|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlmyTWM2OD1|ND6wNUBvVQ>? M4f6NHNCVkeHUh?=
A673 NFKydopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jWcGlEPTB;M{SuNVchdk1? NYTkbXU1W0GQR1XS
VM-CUB-1 M2X4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2L0ZmlEPTB;M{SuOlkhdk1? NIi4SnpUSU6JRWK=
HH MlfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXOybY9vUUN3ME2zOU4xPiCwTR?= M4\NUXNCVkeHUh?=
CAL-27 NXrNVGx6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTMTWM2OD1|NT6xOkBvVQ>? MonSV2FPT0WU
NEC8 NIHKdYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jIbGlEPTB;M{WuN|chdk1? Mo[2V2FPT0WU
BxPC-3 MnzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfRTWM2OD1|Nj65NUBvVQ>? MV7TRW5ITVJ?
SNB75 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnWUmczUUN3ME2zO{4zPCCwTR?= NFLsUolUSU6JRWK=
NB13 NHz3SHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPNWY9YUUN3ME2zPE4zOyCwTR?= M4Hh[nNCVkeHUh?=
SK-OV-3 NFfPTmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fCOmlEPTB;M{iuO|Qhdk1? MYXTRW5ITVJ?
ME-180 NYCyTGZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XiPWlEPTB;M{iuPEBvVQ>? MXvTRW5ITVJ?
JiyoyeP-2003 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Lkb2lEPTB;M{muN|ghdk1? NFPF[FdUSU6JRWK=
LU-134-A M4LnUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHCTWM2OD12MD6wNkBvVQ>? MYLTRW5ITVJ?
LS-123 NXe2NYZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTRyLkK4JI5O NGDhTFNUSU6JRWK=
COLO-800 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\qPGlEPTB;NECuOVYhdk1? NEjYXW9USU6JRWK=
LB831-BLC Mnq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTRzLki1JI5O MWLTRW5ITVJ?
NCI-H747 MkL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTR{LkK4JI5O MWXTRW5ITVJ?
MZ7-mel NVnTU3JwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{C0SmlEPTB;NEKuOlYhdk1? MVjTRW5ITVJ?
GT3TKB Mn;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTR{LkeyJI5O MoOyV2FPT0WU
MOLT-16 M1TvUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDkSXlKSzVyPUSzMlA2KG6P NV\Be2kxW0GQR1XS
23132-87 Ml;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3z5UmlEPTB;NEOuNFUhdk1? NXLibXZGW0GQR1XS
PF-382 NH\McnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDDfmxLUUN3ME20OE4zOiCwTR?= MX3TRW5ITVJ?
ES3 MkS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjhdpRKSzVyPUS0MlYhdk1? M3\VPHNCVkeHUh?=
SW756 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTR3LkG0JI5O NIr5epNUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]

Protocol

Solubility (25°C)

In vitro DMSO 52 mg/mL (197.56 mM)
Water 52 mg/mL warmed (197.56 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water (warmed)
For best results, use promptly after mixing.
52mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 263.2
Formula

C9H11F2N3O4

CAS No. 95058-81-4
Storage powder
in solvent
Synonyms LY-188011, NSC 613327

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03739619 Not yet recruiting Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|Classical Hodgkin Lymphoma|Hodgkin Lymphoma Emory University|Bristol-Myers Squibb November 1 2019 Phase 1|Phase 2
NCT03541486 Not yet recruiting Pancreatic Neoplasm Joseph J. Cullen|Holden Comprehensive Cancer Center|University of Iowa April 1 2019 Phase 2
NCT03417921 Not yet recruiting Pancreatic Cancer Ability Pharmaceuticals SL|The Cleveland Clinic April 1 2019 Phase 1|Phase 2
NCT03669601 Not yet recruiting Cancer CCTU- Cancer Theme|AstraZeneca|Cambridge University Hospitals NHS Foundation Trust March 31 2019 Phase 1
NCT03690739 Not yet recruiting Recurrent Ovarian Carcinoma AGO Research GmbH February 1 2019 Phase 3
NCT03085004 Not yet recruiting Pancreatic Cyst|EUS-FNA Milton S. Hershey Medical Center January 2019 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between gemcitabine(S1714 ) and Gemcitabine HCl (S1149)?

  • Answer:

    Gemcitabine HCl is the HCl salt form of Gemcitabine. They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products0

Tags: buy Gemcitabine | Gemcitabine ic50 | Gemcitabine price | Gemcitabine cost | Gemcitabine solubility dmso | Gemcitabine purchase | Gemcitabine manufacturer | Gemcitabine research buy | Gemcitabine order | Gemcitabine mouse | Gemcitabine chemical structure | Gemcitabine mw | Gemcitabine molecular weight | Gemcitabine datasheet | Gemcitabine supplier | Gemcitabine in vitro | Gemcitabine cell line | Gemcitabine concentration | Gemcitabine nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID